Singapore markets closed
  • Straits Times Index

    3,269.27
    -32.69 (-0.99%)
     
  • Nikkei

    28,546.98
    +727.65 (+2.62%)
     
  • Hang Seng

    20,175.62
    +93.19 (+0.46%)
     
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • BTC-USD

    24,452.74
    -8.72 (-0.04%)
     
  • CMC Crypto 200

    574.64
    +3.36 (+0.59%)
     
  • S&P 500

    4,280.15
    +72.88 (+1.73%)
     
  • Dow

    33,761.05
    +424.38 (+1.27%)
     
  • Nasdaq

    13,047.19
    +267.27 (+2.09%)
     
  • Gold

    1,818.90
    +11.70 (+0.65%)
     
  • Crude Oil

    91.88
    -2.46 (-2.61%)
     
  • 10-Yr Bond

    2.8490
    -0.0390 (-1.35%)
     
  • FTSE Bursa Malaysia

    1,506.19
    +0.63 (+0.04%)
     
  • Jakarta Composite Index

    7,129.28
    -31.11 (-0.43%)
     
  • PSE Index

    6,699.66
    +18.98 (+0.28%)
     

Sanofi (SNY), GSK COVID Booster Jab Effective Against Omicron

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Sanofi SNY announced data from two clinical studies, which evaluated its new next-generation COVID-19 booster vaccine candidate modeled on the Beta variant of concern. This candidate was developed in partnership with GlaxoSmithKline GSK.

Data from cohort 2 of the phase III VAT02 study demonstrated that patients who received a shot of this next-generation booster showed a significant boost in antibody response above baseline against multiple variant of concerns, including Omicron. While there was a 30-fold increase in antibody titers against the Beta variant, preliminary data showed a 40-fold increase against the BA.1 sub-variant of the Omicron strain. The study enrolled participants who were previously vaccinated with an mRNA-based COVID-19 vaccine.

Sanofialso reported results from an independently conducted study COVIBOOST (VAT013), which also evaluated the next-generation booster shot in participants who had completed a primary two-dose regimen of Pfizer PFE/BioNTech’s BNTX mRNA-based vaccine.

Data from the COVIBOOST study showed that candidates who received the Sanofi-GSK next-generation booster vaccine candidate elicited a higher immune response than those who received a booster dose of the Pfizer/BioNTech vaccine as well as Sanofi-GSK’s first-generation parent booster candidate. Pfizer and BioNTech currently market their COVID-19 vaccine under the trade name Comirnaty.

In the year so far, shares of Sanofi have risen 1.6% compared with the industry’s 1% increase.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Per Sanofi, the next-generation booster vaccine candidate was developed keeping in view the emergence of the new COVID-19 variants as well as waning immunity. The candidate was modelled on the Beta variant as it carries similar mutations, which were also found in multiple variants of concern, including Omicron.

Both Sanofi and Glaxo already developed a first-generation recombinant COVID-19 vaccine as a primary vaccine and a booster, which is designed to boost all currently approved COVID-19 vaccine platforms (includes mRNA, protein and adenovirus-based vaccines). This vaccine is yet to be approved/authorized by any regulatory body. The European Medicines Agency (EMA) is currently reviewing SNY’s regulatory filing seeking conditional marketing authorization for the recombinant COVID-19 vaccine.

Both Sanofi and Glaxo plan to initiate regulatory submissions seeking approval/authorization for the next-generation candidate based on the above-mentioned data in a few weeks with plans for a commercial launch by this year-end.

Both companies are developing the COVID-19 vaccines as part of a collaboration agreement reached in 2020. Per the terms of the same, SNY contributed its recombinant antigen while GSK contributed its pandemic adjuvant technology to the development of these candidate. Sanofi is leading the clinical development.

Sanofi Price

Sanofi Price
Sanofi Price

Sanofi price | Sanofi Quote

Zacks Rank

Sanofi currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting